Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Platten

Showing results (261-270 of 318) with videos related to

Pageof 32
Sort By:
Journal for Immunotherapy of Cancer|September 22, 2025
ESPEC-SUIT: a versatile and robust platform to identify and track antigen-specific T cell receptors in patients with cancerKatharina Lindner, Saskia R Stange, Julian Benedikt Hlawatsch, et al.
Science Advances|February 2, 2024
T-FINDER: A highly sensitive, pan-HLA platform for functional T cell receptor and ligand discoveryMiray Cetin, Veronica Pinamonti, Theresa Schmid, et al.
Nature Cancer|July 1, 2026
IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trialLukas Bunse, Katharina Lindner, Antje Wick, et al.
Acta Neuropathologica|July 4, 2018
Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experienceDavid Capper, Damian Stichel, Felix Sahm, et al.
Nature Communications|February 11, 2023
T cell-independent eradication of experimental glioma by intravenous TLR7/8-agonist-loaded nanoparticlesVerena Turco, Kira Pfleiderer, Jessica Hunger, et al.
Nature|March 25, 2021
A vaccine targeting mutant IDH1 in newly diagnosed gliomaMichael Platten, Lukas Bunse, Antje Wick, et al.
Acta Neuropathologica|January 27, 2017
Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivoStefan Pusch, Sonja Krausert, Viktoria Fischer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 31, 2024
Cerebrospinal Fluid cfDNA Sequencing for Classification of Central Nervous System GliomaFlorian Iser, Felix Hinz, Dirk C Hoffmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2016
Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)Wolfgang Wick, Thierry Gorlia, Pierre Bady, et al.
Acta Neuropathologica|June 20, 2015
Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entitiesDavid E Reuss, Annekathrin Kratz, Felix Sahm, et al.
Pageof 32

Showing results (261-270 of 318) with videos related to

Sort By:
Pageof 32
Journal for Immunotherapy of Cancer|September 22, 2025
ESPEC-SUIT: a versatile and robust platform to identify and track antigen-specific T cell receptors in patients with cancerKatharina Lindner, Saskia R Stange, Julian Benedikt Hlawatsch, et al.
Science Advances|February 2, 2024
T-FINDER: A highly sensitive, pan-HLA platform for functional T cell receptor and ligand discoveryMiray Cetin, Veronica Pinamonti, Theresa Schmid, et al.
Nature Cancer|July 1, 2026
IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trialLukas Bunse, Katharina Lindner, Antje Wick, et al.
Acta Neuropathologica|July 4, 2018
Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experienceDavid Capper, Damian Stichel, Felix Sahm, et al.
Nature Communications|February 11, 2023
T cell-independent eradication of experimental glioma by intravenous TLR7/8-agonist-loaded nanoparticlesVerena Turco, Kira Pfleiderer, Jessica Hunger, et al.
Nature|March 25, 2021
A vaccine targeting mutant IDH1 in newly diagnosed gliomaMichael Platten, Lukas Bunse, Antje Wick, et al.
Acta Neuropathologica|January 27, 2017
Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivoStefan Pusch, Sonja Krausert, Viktoria Fischer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 31, 2024
Cerebrospinal Fluid cfDNA Sequencing for Classification of Central Nervous System GliomaFlorian Iser, Felix Hinz, Dirk C Hoffmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2016
Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)Wolfgang Wick, Thierry Gorlia, Pierre Bady, et al.
Acta Neuropathologica|June 20, 2015
Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entitiesDavid E Reuss, Annekathrin Kratz, Felix Sahm, et al.
Pageof 32